Company's Patent Portfolio Continues to Expand as Programs Progress
New York, NY -- (SBWIRE) -- 03/09/2016 -- Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B. A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a subsequent patent with similar claims.
Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals said, "This provisional patent application represents another valuable addition to our intellectual property portfolio. We remain committed to the strategic enhancement of our intellectual property portfolio in alignment with our development of targeted payload immunotherapeutics."
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, "2016 will be a transformational year for Actinium as we transition to a later stage company with the commencement of the Iomab-B Phase 3 pivotal trial and the Actimab-A Phase 2 clinical trial. The strengthening of our intellectual property portfolio is an integral aspect of Actinium's growth and today's provisional patent application demonstrates our commitment to this goal."
Actinium's broad intellectual property portfolio includes 39 issued and pending patents in the U.S. and internationally. This includes 7 issued patents in the United States, 2 pending patents in the United States and 30 issued or pending international patents. The Company's patent portfolio encompasses the use of alpha emitting isotopes attached to monoclonal antibodies, methods for manufacturing key components of its product candidates and methods for manufacturing finished product candidates for use in cancer treatment.
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on healthiest tissues.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (http://www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha -emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.